Conference
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Abstract
Standard cytotoxic treatments for neuroendocrine tumours have been associated with limited activity and remarkable toxicity. A phase II study was designed to evaluate the efficacy, safety and pharmacodynamics of temsirolimus in patients with advanced neuroendocrine carcinoma (NEC). Thirty-seven patients with advanced progressive NEC received intravenous weekly doses of 25 mg of temsirolimus. Patients were evaluated for tumour response, time to …
Authors
Duran I; Kortmansky J; Singh D; Hirte H; Kocha W; Goss G; Le L; Oza A; Nicklee T; Ho J
Volume
95
Pagination
pp. 1148-1154
Publisher
Springer Nature
Publication Date
November 2006
DOI
10.1038/sj.bjc.6603419
Conference proceedings
British Journal of Cancer
Issue
9
ISSN
0007-0920
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntineoplastic AgentsCarcinoid TumorCarcinoma, NeuroendocrineDisease ProgressionExanthemaFatigueFemaleFollow-Up StudiesHumansHyperglycemiaInfusions, IntravenousMaleMiddle AgedPancreatic NeoplasmsPhosphorylationProtein KinasesProto-Oncogene Proteins c-aktRibosomal Protein S6SirolimusSurvival AnalysisTOR Serine-Threonine KinasesTreatment Outcome